Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy

BACKGROUND: To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemaciclib (ABM) plus FUL in Italy. Cost-effectiveness analysis comparing the three cyclin-dependent 4/6 kinase inhibitors in combination with endocrine therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Giorgio Lorenzo, Valentino, Maria Chiara, Fabi, Alessandra, Dieci, Maria Vittoria, Caruggi, Mauro, Bruno, Giacomo Matteo, Lombardi, Gloria, Di Matteo, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066701/
https://www.ncbi.nlm.nih.gov/pubmed/37013197
http://dx.doi.org/10.2147/TCRM.S391769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066701/
https://www.ncbi.nlm.nih.gov/pubmed/37013197
http://dx.doi.org/10.2147/TCRM.S391769

Ejemplares similares